查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1808861

尿路上皮癌診斷市場，依檢測類型、癌症類型、最終用戶、國家及地區分類－2025 年至 2032 年全球產業分析、市場規模、市場佔有率及預測

Urothelial Carcinoma Diagnostics Market, By Test Type, By Cancer Type, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年尿路上皮癌診斷市場規模價值 19.8776 億美元，2025 年至 2032 年的複合年成長率為 9.8%。

尿路上皮癌診斷市場專注於用於檢測和監測尿路上皮癌的工具、檢測和技術。尿路上皮癌是一種常見的膀胱癌，會影響泌尿道內壁。該市場的診斷方法包括尿液細胞學檢查、膀胱鏡檢查、影像學檢查（CT、MRI）以及分子檢測，例如螢光原位雜合技術 (FISH) 和 NMP22 蛋白檢測。早期檢測至關重要，因為它可以改善治療效果並降低疾病進展風險。膀胱癌發病率的上升、認知度的提高以及對非侵入性檢測方法日益成長的需求推動著市場的發展。

液體活體組織切片和基於生物標記的檢測等技術進步進一步推動了市場成長。醫院、診斷實驗室和研究機構是主要的終端使用者。北美憑藉其強大的醫療基礎設施和較高的診斷率佔據市場主導地位。監管部門的批准以及檢測靈敏度和特異性方面的創新持續塑造著市場格局。

尿路上皮癌診斷市場-市場動態

提高對永續成長的認知以推動市場需求

尿路上皮癌診斷市場的一個利基促進因素是尿液生物標記在早期非侵入性膀胱癌檢測中的應用日益廣泛。膀胱鏡檢查等傳統診斷工具具有侵入性，患者操作不便，且價格昂貴。相較之下，尿液生物標記提供了一種侵入性較低、更方便患者的尿路上皮癌診斷方法。這些生物標記可以檢測尿液樣本中的基因突變、蛋白質水平和其他分子變化，從而提示是否有癌症。

NMP22、UroVysion (FISH) 和膀胱腫瘤抗原 (BTA) 等檢測在臨床監測和初步診斷的應用日益廣泛。這些檢測更加便捷，可重複檢測，並在許多情況下減少了侵入性操作的需求。對於因膀胱癌高復發率而需要頻繁監測的患者而言，這一趨勢尤其重要。

此外，基因組學和蛋白​​質組學的進展正在推動發現新的尿液生物標記物，其靈敏度和特異性均有所提高。這些創新提高了診斷的準確性，使其成為早期癌症檢測的寶貴工具。隨著精準醫療日益受到重視，醫療保健提供者正在尋求可靠且經濟高效的診斷解決方案，這進一步推動了向尿液生物標記檢測的轉變。這種日益成長的偏好正在塑造尿路上皮癌診斷的未來，尤其是在門診和資源受限的環境中。

尿路上皮癌診斷市場－關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 9.8%。

根據測試類型細分，膀胱鏡檢查預計將在 2024 年佔據最大市場佔有率

根據癌症類型細分，非肌肉層浸潤性膀胱癌是 2024 年的主要癌症類型

根據最終用戶細分，醫院是 2024 年的主要最終用戶

按地區分類，北美是 2024 年的主要收入來源

尿路上皮癌診斷市場-細分分析：

全球尿路上皮癌診斷市場根據測試類型、癌症類型、最終用戶和地區進行細分。

根據檢測類型，市場分為五類：尿液細胞學檢查、膀胱鏡檢查、免疫測定、螢光原位雜合技術 (FISH)、生物標記檢測、PCR 檢測及其他。按檢測類型分類，尿路上皮癌診斷市場中最主要的細分市場是膀胱鏡檢查。由於其準確性高，並且能夠直覺地檢查膀胱內壁是否存在腫瘤，該檢查仍然是診斷和監測膀胱癌的黃金標準。儘管膀胱鏡檢查屬於侵入性檢查，但如果發現可疑病變，則可以進行活體組織切片並立即進行干預。臨床醫生高度依賴膀胱鏡檢查，尤其是對於復發性或高風險膀胱癌患者，這使其成為診斷領域的領先地位。膀胱鏡檢查已確立的臨床實用性以及在醫院和泌尿外科中心的廣泛應用鞏固了其主導地位。

根據癌症類型，市場分為兩類：非肌肉浸潤性膀胱癌 (NMIBC) 和肌肉層浸潤性膀胱癌 (MIBC)。在尿路上皮癌診斷市場中，依癌症類型分類，最主要的細分市場是非肌肉層浸潤性膀胱癌 (NMIBC)。 NMIBC 佔初次診斷膀胱癌病例的大多數，因此早期和反覆的診斷檢測至關重要。由於 NMIBC 患者復發率高，他們通常需要定期監測，這促使他們經常使用膀胱鏡檢查、尿液細胞學檢查和生物標記檢測等診斷工具。這種持續的監測顯著增加了該細分市場對診斷產品的需求，使 NMIBC 成為市場成長的主要動力。

尿路上皮癌診斷市場—地理洞察

北美地區尿路上皮癌診斷市場格局以強大的醫療基礎設施、較高的癌症篩檢率以及先進診斷技術的快速普及為特徵。美國憑藉其膀胱癌的高發病率、健全的報銷體係以及積極的腫瘤診斷研究經費，在該地區處於領先地位。 FDA 等機構的監管支持加速了基於新型生物標記和分子診斷檢測的批准和商業化。

加拿大也貢獻良多，這得益於人們日益成長的認知度以及政府支持早期癌症檢測的措施。該地區的主要參與者經常與學術機構和醫院合作，開發和試行創新的診斷解決方案。由於完善的診斷實驗室網路和高度集中的精準醫療計劃，北美市場已成為尖端尿路上皮癌診斷技術的樞紐。

尿路上皮癌診斷市場-競爭格局：

尿路上皮癌診斷市場的競爭格局由老牌診斷巨頭和創新生物技術公司共同構成。羅氏診斷、雅培和賽默飛世爾科技等公司憑藉全面的診斷產品組合、全球終端用戶網路和雄厚的研發投入，佔據了市場主導地位。這些公司提供先進的分子和免疫分析檢測，通常與數位病理學和實驗室自動化解決方案捆綁銷售，使其在大型醫療保健系統中佔據戰略優勢。

同時，Myriad Genetics、Natera 和 Biocept 等專業公司專注於精準診斷，尤其是膀胱癌的液體活體組織切片和基因組分析，為市場注入了活力。這些公司正在利用新一代定序 (NGS)、尿液生物標記和人工智慧的進步來提高診斷的靈敏度和特異性。他們的創新滿足了人們對非侵入性、精準且患者友好的診斷日益成長的需求，尤其是在高風險和復發病例中。

最新動態：

2024年6月，ALX Oncology Holdings Inc. 在2024年美國臨床腫瘤學會 (ASCO) 年會上透過壁報展示（摘要編號#4575）分享了其1期ASPEN-07臨床試驗的結果。此資料是首次通報evorpacept與抗體藥物偶聯物（具體為PADCEV (enfortumab vedotin)）合併用藥，研究正在進行一項開放標籤、單組試驗，受試者為局部晚期或轉移性尿路上皮癌患者。

目錄

第1章：尿路上皮癌診斷市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 尿路上皮癌診斷市場片段（依檢驗類型）
    • 尿路上皮癌診斷市場（按癌症類型）
    • 尿路上皮癌診斷市場片段（依最終用戶）
    • 尿路上皮癌診斷市場（按國家/地區）
    • 尿路上皮癌診斷市場（按地區）
  • 競爭洞察

第3章：尿路上皮癌診斷主要市場趨勢

  • 尿路上皮癌診斷市場促進因素
    • 市場促進因素的影響分析
  • 尿路上皮癌診斷市場限制
    • 市場限制的影響分析
  • 尿路上皮癌診斷市場機遇
  • 尿路上皮癌診斷市場未來趨勢

第4章：尿路上皮癌診斷產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：尿路上皮癌診斷市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：尿路上皮癌診斷市場格局

  • 2024年尿路上皮癌診斷市佔分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：尿路上皮癌診斷市場－依檢測類型

  • 概述
    • 按測試類型分類的細分市場佔有率分析
    • 尿液細胞學檢查
    • 膀胱鏡檢查
    • 免疫測定
    • 螢光原位雜合技術（FISH）
    • 生物標記測試
    • 基於PCR的檢測
    • 其他

第 8 章：尿路上皮癌診斷市場 - 按癌症類型

  • 概述
    • 按癌症類型分類的細分佔有率分析
    • 非肌肉層浸潤性膀胱癌（NMIBC）
    • 肌肉層浸潤性膀胱癌（MIBC）

第9章：尿路上皮癌診斷市場－按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院
    • 診斷實驗室
    • 癌症研究機構
    • 門診手術中心
    • 學術與研究中心

第 10 章：尿路上皮癌診斷市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美尿路上皮癌診斷主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按測試類型）
    • 北美市場規模及預測（按癌症類型）
    • 北美市場規模及預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲尿路上皮癌診斷主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模和預測（按測試類型）
    • 歐洲市場規模及預測（按癌症類型）
    • 歐洲市場規模及預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區尿路上皮癌診斷主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依測試類型）
    • 亞太地區市場規模及預測（依癌症類型）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲尿路上皮癌診斷主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按測試類型）
    • 拉丁美洲市場規模及預測（按癌症類型）
    • 拉丁美洲市場規模及預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲尿路上皮癌診斷主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依測試類型）
    • MEA 市場規模及預測（以癌症類型）
    • MEA 市場規模及預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 11 章：關鍵供應商分析-尿路上皮癌診斷產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Roche Diagnostics
    • Abbott Laboratories
    • Thermo Fisher Scientific
    • Qiagen
    • Bio-Rad Laboratories
    • Illumina, Inc.
    • Hologic, Inc.
    • Agilent Technologies
    • Myriad Genetics
    • Danaher Corporation
    • Siemens Healthineers
    • Sysmex Corporation
    • Becton, Dickinson and Company (BD)
    • Genomic Health
    • Epigenomics AG
    • Bio-Techne Corporation
    • Natera, Inc.
    • Guardant Health
    • Exact Sciences Corporation
    • Biocept, Inc.

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5515

Urothelial Carcinoma Diagnostics Market size was valued at US$ 1,987.76 Million in 2024, expanding at a CAGR of 9.8% from 2025 to 2032.

The Urothelial Carcinoma Diagnostics Market focuses on the tools, tests, and technologies used to detect and monitor urothelial carcinoma, a common type of bladder cancer affecting the urinary tract's lining. Diagnostics in this market include urine cytology, cystoscopy, imaging techniques (CT, MRI), and the molecular tests such as fluorescence in situ hybridization (FISH) and NMP22 protein tests. Early detection is vital as it improves treatment outcomes and reduces disease progression risks. The market is driven by the rising incidence of bladder cancer, increasing awareness, and growing demand for non-invasive testing methods.

Technological advancements like liquid biopsy and biomarker-based tests are further fueling growth. Hospitals, diagnostic labs, and research institutions are the main end users. North America dominates the market due to strong healthcare infrastructure and high diagnostic rates. Regulatory approvals and innovation in test sensitivity and specificity continue to shape the market landscape.

Urothelial Carcinoma Diagnostics Market- Market Dynamics

Increasing awareness about sustainable growth to propel market demand

One niche driver of the Urothelial Carcinoma Diagnostics Market is the rising adoption of urinary biomarkers for early, non-invasive bladder cancer detection. Traditional diagnostic tools like cystoscopy are invasive, uncomfortable for patients, and costly. In contrast, urinary biomarkers offer a less invasive and more patient-friendly alternative for identifying urothelial carcinoma. These biomarkers can detect genetic mutations, protein levels, and other molecular changes in urine samples that indicate the presence of cancer.

Tests like NMP22, UroVysion (FISH), and bladder tumor antigen (BTA) are increasingly being used in clinical settings for surveillance and initial diagnosis. They provide a higher level of convenience, enable repeat testing, and reduce the need for invasive procedures in many cases. This trend is particularly significant for patients requiring frequent monitoring due to high recurrence rates of bladder cancer.

Additionally, advances in genomics and proteomics are leading to the discovery of new urinary biomarkers with improved sensitivity and specificity. These innovations enhance diagnostic accuracy, making them valuable tools for early-stage cancer detection. As precision medicine becomes more prominent, healthcare providers are seeking reliable, cost-effective diagnostic solutions, further supporting the shift toward urine-based biomarker testing. This growing preference is helping shape the future of urothelial carcinoma diagnostics, especially in outpatient and resource-constrained settings.

Urothelial Carcinoma Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.8% over the forecast period (2025-2032)

Based on Test Type segmentation, Cystoscopy was predicted to show maximum market share in the year 2024

Based on Cancer Type segmentation, Non-Muscle Invasive Bladder Cancer was the leading Cancer Type in 2024

Based on end-user segmentation, Hospitals was the leading end-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Urothelial Carcinoma Diagnostics Market- Segmentation Analysis:

The Global Urothelial Carcinoma Diagnostics Market is segmented on the basis of Test Type, Cancer Type, End-user, and Region.

The market is divided into five categories based on Test Type: Urine Cytology, Cystoscopy, Immunoassays, Fluorescence in Situ Hybridization (FISH), Biomarker Tests, PCR-Based Tests, and Others. The most dominant segment in the Urothelial Carcinoma Diagnostics Market by test type is Cystoscopy. This procedure remains the gold standard for diagnosing and monitoring bladder cancer due to its high accuracy and ability to visually inspect the bladder lining for tumors. Despite being invasive, it allows for biopsy and immediate intervention if suspicious lesions are detected. Clinicians rely heavily on cystoscopy, especially in patients with recurrent or high-risk bladder cancer, contributing to its leading position in the diagnostics landscape. Its established clinical utility and widespread adoption in hospitals and urology centers solidify its dominance.

The market is divided into two categories based on Cancer Type: Non-Muscle Invasive Bladder Cancer (NMIBC), Muscle Invasive Bladder Cancer (MIBC). The most dominant segment by cancer type in the Urothelial Carcinoma Diagnostics Market is Non-Muscle Invasive Bladder Cancer (NMIBC). NMIBC accounts for the majority of bladder cancer cases at initial diagnosis, making early and repeated diagnostic testing essential. Patients with NMIBC often undergo regular surveillance due to high recurrence rates, driving frequent use of diagnostic tools such as cystoscopy, urine cytology, and biomarker tests. This ongoing monitoring significantly increases the demand for diagnostics in this segment, making NMIBC the leading contributor to market growth.

Urothelial Carcinoma Diagnostics Market- Geographical Insights

The North American regional landscape for the Urothelial Carcinoma Diagnostics Market is marked by strong healthcare infrastructure, high cancer screening rates, and rapid adoption of advanced diagnostic technologies. The United States leads the region due to a high prevalence of bladder cancer, robust reimbursement systems, and active research funding for oncology diagnostics. Regulatory support from bodies like the FDA accelerates the approval and commercialization of novel biomarker-based and molecular diagnostic tests.

Canada also contributes steadily, driven by growing awareness and government initiatives supporting early cancer detection. Key players in the region frequently collaborate with academic institutions and hospitals to develop and pilot innovative diagnostic solutions. The market benefits from a well-established network of diagnostic laboratories and a high concentration of precision medicine initiatives, making North America a hub for cutting-edge urothelial carcinoma diagnostic advancements.

Urothelial Carcinoma Diagnostics Market- Competitive Landscape:

The competitive landscape of the Urothelial Carcinoma Diagnostics Market is shaped by the presence of established diagnostics giants alongside innovative biotech firms. Companies like Roche Diagnostics, Abbott, and Thermo Fisher Scientific dominate the market with comprehensive diagnostic portfolios, global End-user networks, and high R&D investment. These firms offer advanced molecular and immunoassay-based tests, often bundled with digital pathology and laboratory automation solutions, giving them a strategic edge in large healthcare systems.

Meanwhile, specialized companies such as Myriad Genetics, Natera, and Biocept are contributing to market dynamism by focusing on precision diagnostics, especially liquid biopsy and genomic profiling for bladder cancer. These firms are leveraging advancements in next-generation sequencing (NGS), urinary biomarkers, and artificial intelligence to improve diagnostic sensitivity and specificity. Their innovations cater to the growing demand for non-invasive, accurate, and patient-friendly diagnostics, especially for high-risk and recurrent cases.

Recent Developments:

In June 2024, ALX Oncology Holdings Inc. shared results from its Phase 1 ASPEN-07 clinical trial through a poster presentation (abstract #4575) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data marked the first report of evorpacept used in combination with an antibody-drug conjugate, specifically PADCEV (enfortumab vedotin), in an ongoing open-label, single-arm trial involving patients with locally advanced or metastatic urothelial carcinoma.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Qiagen
  • Bio-Rad Laboratories
  • Illumina, Inc.
  • Hologic, Inc.
  • Agilent Technologies
  • Myriad Genetics
  • Danaher Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Becton, Dickinson and Company (BD)
  • Genomic Health
  • Epigenomics AG
  • Bio-Techne Corporation
  • Natera, Inc.
  • Guardant Health
  • Exact Sciences Corporation
  • Biocept, Inc.

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

  • Urine Cytology
  • Cystoscopy
  • Immunoassays
  • Fluorescence In Situ Hybridization (FISH)
  • Biomarker Tests
  • PCR-Based Tests
  • Others

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Non-Muscle Invasive Bladder Cancer (NMIBC)
  • Muscle Invasive Bladder Cancer (MIBC)

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Academic & Research Centers

GLOBAL UROTHELIAL CARCINOMA DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Urothelial Carcinoma Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Urothelial Carcinoma Diagnostics Market Snippet by Test Type
    • 2.1.2. Urothelial Carcinoma Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Urothelial Carcinoma Diagnostics Market Snippet by End-user
    • 2.1.4. Urothelial Carcinoma Diagnostics Market Snippet by Country
    • 2.1.5. Urothelial Carcinoma Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Urothelial Carcinoma Diagnostics Key Market Trends

  • 3.1. Urothelial Carcinoma Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Urothelial Carcinoma Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Urothelial Carcinoma Diagnostics Market Opportunities
  • 3.4. Urothelial Carcinoma Diagnostics Market Future Trends

4. Urothelial Carcinoma Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Urothelial Carcinoma Diagnostics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Urothelial Carcinoma Diagnostics Market Landscape

  • 6.1. Urothelial Carcinoma Diagnostics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Urothelial Carcinoma Diagnostics Market - By Test Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Test Type, 2024 & 2032 (%)
    • 7.1.2. Urine Cytology
    • 7.1.3. Cystoscopy
    • 7.1.4. Immunoassays
    • 7.1.5. Fluorescence In Situ Hybridization (FISH)
    • 7.1.6. Biomarker Tests
    • 7.1.7. PCR-Based Tests
    • 7.1.8. Others

8. Urothelial Carcinoma Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
    • 8.1.2. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 8.1.3. Muscle Invasive Bladder Cancer (MIBC)

9. Urothelial Carcinoma Diagnostics Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Diagnostic Laboratories
    • 9.1.4. Cancer Research Institutes
    • 9.1.5. Ambulatory Surgical Centers
    • 9.1.6. Academics & Research Centers

10. Urothelial Carcinoma Diagnostics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Urothelial Carcinoma Diagnostics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Urothelial Carcinoma Diagnostics Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Urothelial Carcinoma Diagnostics Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Roche Diagnostics
    • 11.2.2. Abbott Laboratories
    • 11.2.3. Thermo Fisher Scientific
    • 11.2.4. Qiagen
    • 11.2.5. Bio-Rad Laboratories
    • 11.2.6. Illumina, Inc.
    • 11.2.7. Hologic, Inc.
    • 11.2.8. Agilent Technologies
    • 11.2.9. Myriad Genetics
    • 11.2.10. Danaher Corporation
    • 11.2.11. Siemens Healthineers
    • 11.2.12. Sysmex Corporation
    • 11.2.13. Becton, Dickinson and Company (BD)
    • 11.2.14. Genomic Health
    • 11.2.15. Epigenomics AG
    • 11.2.16. Bio-Techne Corporation
    • 11.2.17. Natera, Inc.
    • 11.2.18. Guardant Health
    • 11.2.19. Exact Sciences Corporation
    • 11.2.20. Biocept, Inc.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us